Literature DB >> 3082590

The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids.

P Crawford, D Chadwick, P Cleland, J Tjia, A Cowie, D J Back, M L Orme.   

Abstract

Patients taking anticonvulsants such as phenobarbitone, phenytoin and carbamazepine together with their oral contraceptive steroid may suffer contraceptive failure because of the enzyme-inducing properties of these anticonvulsants. We have examined, in six women, the effect of sodium valproate, an effective broad spectrum anticonvulsant, on the area under the plasma concentration versus time profile (AUC) of ethinyloestradiol (EE2) and levonorgestrel (Ng). Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4). Between two and four months after sodium valproate therapy the mean AUC figures had not changed significantly, the figure for EE2 being 977 +/- 130 pg/ml X h and for levonorgestrel 29.2 +/- 1.9 ng/ml X h (p greater than or equal to 0.1 in each case). We conclude that sodium valproate in the dose used (200 mg b.d.) does not interact with oral contraceptive steroids.

Entities:  

Keywords:  Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen--administraction and dosage; Contraceptive Agents, Female; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents--administraction and dosage; Contraceptive Methods--pharmacodynamics; Drugs--pharmacodynamics; Endocrine System; Ethinyl Estradiol--administraction and dosage; Family Planning; Hormones; Levonorgestrel; Oral Contraceptives--pharmacodynamics; Physiology; Reproductive Control Agents; Treatment

Mesh:

Substances:

Year:  1986        PMID: 3082590     DOI: 10.1016/0010-7824(86)90028-4

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  15 in total

Review 1.  Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.

Authors:  K Wilbur; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

2.  Anti-epileptic drugs and hormonal treatments.

Authors:  Clare A Johnston; Pamela M Crawford
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

Review 3.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

4.  Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.

Authors:  D J Back; S F Grimmer; M L Orme; C Proudlove; R D Mann; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

5.  Seizure facilitating activity of the oral contraceptive ethinyl estradiol.

Authors:  Iyan Younus; Doodipala Samba Reddy
Journal:  Epilepsy Res       Date:  2016-01-27       Impact factor: 3.045

6.  Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.

Authors:  Robert DiCenzo; Derick Peterson; Kim Cruttenden; Gene Morse; Garret Riggs; Harris Gelbard; Giovanni Schifitto
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

7.  Do oral contraceptives increase epileptic seizures?

Authors:  Doodipala Samba Reddy
Journal:  Expert Rev Neurother       Date:  2016-10-12       Impact factor: 4.618

Review 8.  Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.

Authors:  James W McAuley; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Managing epilepsy in women of childbearing age.

Authors:  Pamela M Crawford
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 10.  Oral contraceptives. Are drug interactions of clinical significance?

Authors:  G M Shenfield
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.